GLP-1 receptor agonists in idiopathic subglottic stenosis: patient attitudes, barriers, facilitators and patient-reported outcomes

Purpose Idiopathic subglottic stenosis (iSGS) is a rare disease of unknown etiology. There has been a growing interest within the patient community regarding the potential therapeutic role of GLP-1 receptor agonists (GLP-1 RA) in the management of iSGS, potentially through weight loss-mediated or direct anti-inflammatory mechanisms. The objective of this study was to evaluate patient perspectives and attitudes regarding the potential role of GLP-1 RA in the overall management of iSGS. Methods We conducted a cross-sectional observational study through a structured online anonymous survey. The survey comprised 53 items organized across four domains: demographics; attitudes, barriers and facilitators to GLP-1 RA use; therapy details and adverse effects; and perceived therapeutic impact. Results A total of 1382 patients with iSGS completed the survey. Diagnostic delay of iSGS was a prominent finding, with patients reporting a substantial lag between symptom onset and confirmed diagnosis. Overall, 407 patients used GLP-1 RA therapy. Among GLP-1 RA users, 38.44% self-reported perceived improvement in airway symptoms. Key barriers to GLP-1 RA therapy included cost, access, and limited physician awareness. Thematic analysis of the patient’s responses revealed patients’ attitudes toward GLP-1 RA therapy were largely favorable, with patients citing anti-inflammatory benefits and quality of life improvements as primary motivators for use. Conclusion GLP-1 receptor agonists are generally viewed favorably by patients with iSGS. Patient-reported experiences suggest possible improvements in airway symptoms, although prospective studies are required to establish causality and clarify mechanistic benefit.

Authors

Institutions

Publication Details

Journal
European Archives of Oto-Rhino-Laryngology
Published
2026-11-21
DOI
https://doi.org/10.1007/s00405-026-10835-3
Primary Topic
Tracheal and airway disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

GLP-1 receptor agonists in idiopathic subglottic stenosis: patient attitudes, barriers, facilitators and patient-reported outcomes

Chadwan Al Yaghchi, Laura-Élisabeth Gosselin, Catherine Anderson
European Archives of Oto-Rhino-Laryngology
Tracheal and airway disorders
article

GLP-1 receptor agonists in idiopathic subglottic stenosis: patient attitudes, barriers, facilitators and patient-reported outcomes

Chadwan Al Yaghchi, Laura-Élisabeth Gosselin, Catherine Anderson
article en

Abstract

Purpose Idiopathic subglottic stenosis (iSGS) is a rare disease of unknown etiology. There has been a growing interest within the patient community regarding the potential therapeutic role of GLP-1 receptor agonists (GLP-1 RA) in the management of iSGS, potentially through weight loss-mediated or direct anti-inflammatory mechanisms. The objective of this study was to evaluate patient perspectives and attitudes regarding the potential role of GLP-1 RA in the overall management of iSGS. Methods We conducted a cross-sectional observational study through a structured online anonymous survey. The survey comprised 53 items organized across four domains: demographics; attitudes, barriers and facilitators to GLP-1 RA use; therapy details and adverse effects; and perceived therapeutic impact. Results A total of 1382 patients with iSGS completed the survey. Diagnostic delay of iSGS was a prominent finding, with patients reporting a substantial lag between symptom onset and confirmed diagnosis. Overall, 407 patients used GLP-1 RA therapy. Among GLP-1 RA users, 38.44% self-reported perceived improvement in airway symptoms. Key barriers to GLP-1 RA therapy included cost, access, and limited physician awareness. Thematic analysis of the patient’s responses revealed patients’ attitudes toward GLP-1 RA therapy were largely favorable, with patients citing anti-inflammatory benefits and quality of life improvements as primary motivators for use. Conclusion GLP-1 receptor agonists are generally viewed favorably by patients with iSGS. Patient-reported experiences suggest possible improvements in airway symptoms, although prospective studies are required to establish causality and clarify mechanistic benefit.

European Archives of Oto-Rhino-Laryngology
Imperial College Healthcare NHS Trust (GB), Université Laval (CA), Imperial College London (GB)
Tracheal and airway disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon